BioSpace News Archive

Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions.

Positron Corporation is pleased to announce that it has ordered five NeuSight PET-CT 64 slice scanners from cooperative partner Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF).

Parallel Bio, a biotech company using the immune system to cure disease, today announced that Ari Gesher has joined as the first head of technology.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial.

CTIBIOTECH™, a pioneering company in the development and production of biological tests on human tissues, is proud to announce the launch of its innovative SAFESKIN3D project.

Mann Eye Institute announces the grand opening of its office-based surgery center, Mann Austin Surgery Center, at 4314 W. Braker Lane, Suite #215, Austin, TX 78759.

Cyclacel Pharmaceuticals, Inc. announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor.

TRex Bio, Inc. (“TRexBio”) today announced that collaboration partner Eli Lilly and Company (“Lilly”) has initiated a Phase 1 first-in-human study of TRB-051, a modulator of immune effector cells, for treatment of autoimmune and inflammatory diseases.

CraniUS™, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain disease, has been awarded a competitive $1 million grant from the State of Maryland as part of Governor Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program.